| mRNA |
UNC1215 |
GDSC1000 |
pan-cancer |
AAC |
0.14 |
4e-05 |
| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
7e-05 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
9e-05 |
| mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.0002 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0002 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0004 |
| mRNA |
PF-184 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.0005 |
| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.0006 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.0007 |
| mRNA |
linifanib |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0007 |